Cancer risk in dermatomyositis: A systematic review of the literature

Giornale Italiano di Dermatologia e Venereologia

Volumn 149, Issue 5, 2014, Pages 525-537

  Di Rollo, D ^a   Abeni, D ^b   Tracanna, M ^a   Capo, A ^a   Amerio, P ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Dermatomyositis; Neoplasms; Skin diseases

Indexed keywords

ARTICLE; CANCER RISK; CLINICAL FEATURE; DATA SYNTHESIS; DERMATOMYOSITIS; HUMAN; MEDICAL LITERATURE; SYSTEMATIC REVIEW; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; COMORBIDITY; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ERYTHEMA; EXANTHEMA; FEMALE; IMMUNOLOGY; MALE; NECROSIS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; PATHOLOGY; RETROSPECTIVE STUDY; RISK; SEX DIFFERENCE; SKIN; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

AUTOANTIBODY;

ANTIBODY SPECIFICITY; AUTOANTIBODIES; CASE-CONTROL STUDIES; COMORBIDITY; DERMATOMYOSITIS; DISEASE SUSCEPTIBILITY; EARLY DETECTION OF CANCER; ERYTHEMA; EXANTHEMA; FEMALE; HUMANS; MALE; NECROSIS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK; SEX FACTORS; SKIN; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

EID: 84925552512     PISSN: 03920488     EISSN: 18271820     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Madam V, Chinoy H, Griffiths CEM, Cooper RG. Defining cancer risk in dermatomyositis. Part 1. Clin Exp Dermatol 2009;34:451-5.
2. Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002;4:415-26.
3. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with Polymyositis and Dermatomyositis. Medicine 1977;56:255-86.
4. Sigurgeirsson B, Lindelof B, Edhag O, Allader E. Risk of cancer in patients with dermatomyositis or polymiositis. A population-based study. N Engl J Med 1992; 326:363-7.
5. Airo A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with Dewrmatomyositis: a population based study. J Rheumatol 1995;22:1300-3.
6. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001;85:41-5.
7. Buchbinder R, Forbes A, Hall S, Dennet X. Incidence of malignant disease in Biopsy-poven Inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001;134:1087-95.
8. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymiositis and dermatomyositis. J Rheumatol 1994;21:1855-9.
9. Hill C, Zhang J, Sigurgeisson B, Pukkala E, Mellemkjaer L, Airo A et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
10. Madam V, Chinoy H, Griffiths CEM, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009;34:561-5.
11. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011;13:208-15.
12. Wang J, Guo G, Chen G, Wu B, Lu L, Bao L. Meta-anaysis ot the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 2013;169:838-47.
13. Azuma K, Yamada H, Ohkubo M, Yamasaki Y, Yamasaki M, Mi-zushima M et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011;21:178-83.
14. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risk of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010;12:R70.
15. Lee SW, Jung SY, Park MC, Park YB, Lee SK. Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 2006;47:519-23.
16. Prohic A, Kasumagic-Hailovic E, Simic D, Selmanagic A. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 2009;23:591-2.
17. Chen YI, Wu CY, Shen JL. Predicting factors of malignancy in der-matomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-31.
18. Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, et al. Malignancies associated with dermatomyositis and polymiositis in Taiwan: a nationwide population-based study. Br J Dermatol 2009;161:854-60.
19. Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998;27:319-24.
20. Fardet L, Dupuy A, Gain M, Kettaneh A, Cherin P, Bachelez H et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine 2009;88:91-7.
21. Sparsa A, Liozon E, Herrmann F, Ly K, Lebrum V, Soria P et al. Routine vs. extensive malignancy search for adult dermatomyositis and polymyositis. Arch Dermatol 2002;138:885-90.
22. Ponyi A, Costantin T, Garami M, Andràs C, Tallai B, Vanesa A et al. Cancer-associated Myositis, clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051:64-71.
23. Hidano A, Kaneko K, Arai Y, Kikuchi R. Survey of the prognosis for dermatomyositis, with special reference to its association with malignancy and pulmonary fibrosis. J Dermatol 1986;13:233-41.
24. Hidano A, Torikai S, Uemura T, Shimizu S. Malignancy and interstitial pneumonitis as fatal complications in Dermatomyositis. J Dermatol 1992;19:153-60.
25. Al-Ballaa SR, Al-Dalaan AN, El-Ramahi KM, Al-Janadi MA, Al-Shaikh A, Bahabri S. Pattern of adult onset of polymyositis and dermatomyositis and association with malignancy. Ann Saudi Med 1993;13:525-9.
26. Parodi A, Caproni M, Marzano AV, De Simone C, La Placa M, Quaglino P et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 2002;82:48-51.
27. Duncan AG, Richardson JB, Klein JB, Targoff IN, WoodcocK TM, Callen JP. Clinical, serologic and immunogenetic studies in patients with Dermatomyositis. Acta Derm Venereol (Stockh) 1990;71:312-6.
28. Vesterager L, Worm AM, Thomsen K. Dermatomyositis and malignancy. Clin Exp Dermatol 1980;5:31-5.
29. Liu WC, Ho M, Koh WP, Tan AW, Ng PPL, Chua SH et al. An 11-year review of dermatomyositis in asian patients. Ann Acad Med Singapore 2010;39:843-7.
30. Callen JP, Hyla JF, Bole GG, Kay DR. The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol 1980;116:295-8.
31. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 2002;41:729-34.
32. Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Ruvuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis, a study of 32 cases. Arch Dermatol 1990;126:633-7.
33. Leow Y, Goh CL. Malignancy in adult dermatomyositis. International Journal of Dermatology 1997;36:904-7.
34. Koh ET, Seow A, Ratnagopal P, Tjia H, Chung HH. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993;52:857-61.
35. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: areview of 105 cases. J Rheumatol 1985;12:1140-8.
36. La Montagna G, Manzo C, Califano E, Tirri R. Absence of elevated creatine kinase in dermatomyositis does not exclude malignancy. Scand J Rheumatology 1988;17:73-4.
37. Cox NH, Lawrence CM, Langtry JAA, Ive FA. Dermatomyositis. Arch Dermatol 1990;126:61-5.
38. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995;6:9-13.
39. Uthman I, Vazqued-Abad D, Senècal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996;26:447-58.
40. Mautner GH, Grossman ME, Silvers DN, Rabinowitz A, Mowad CM, Johnson BL. Epidermal necrosis as a predictive sign of malignancy in adult Dermatomyositis. Cutis 1998;61:190-4.
41. Feldman D, Hochberg MC, Zizic TM, Stevens MB. Cutaneous vasculitis in adult Polymyositis/Dermatomyositis. J Rheumatol 1983;10:85-9.
42. Hunger RE, Durr C, Brand CU. Cutaneous luekocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001;202:123-6.
43. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. Am J Med 1986;80:329-32.
44. Na SJ, Kim SM, Sunwoo N, Choi YC. Clinical characteristics and outcomes of juvenile and adult Dermatomyositis. J Korea Med Sci 2009;24:715-21.
45. Dourmishev LA. Dermatomyositis associated with malignancy. Rheuma Derm 1999;28:193-9.
46. Lakhapal Sharad, Bunh TW, Ilstrup DM, Melton III LJ. Polymy-ositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 1986;61:645-53.
47. Holden DJ, Brownell AKW, Fritzler MJ. Clinical and serological features of patients with polymyositis or dermatomyositis. Can Med Assoc J 1985;132:649-53.
48. Lyon MG, Bloch DA, Hollak B, Fries JF. Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey. J Rheumatol 1989;16:1218-24.
49. Marie I, Haltron PY, Levesque H, Hachulla E, Hellot MF, Pasturel UM, Courtois H et al. Influence of age on characteristics of polymiositis and dermatomyositis in adults. Medicine 1999;78:139-47.
50. Wong KO. Dermatomyositis: a clinical investigation of twenty-three cases in Hong Kong. Br J Derm 1969;81:544-7.
51. Hoffman GS, Franck WA, Raddatz DA, Stallones L. Presentation, treatment, and prognosis of Idiophatic Inflammatory muscle disease in a rural hospital. Am J Med 1983;75:433-8.
52. Bendewald MJ, Wetter DA, Li X, Davis MDP. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. A population-based study in Olmsted County, Minnesota. Arch Dermatol 2010;146:26-30.
53. Nishikai M, Sato A, Low incidence on antinuclear antibodies in dermatomyositis with malignancy. Ann Rheum Dis 1990;49:422.
54. Baron M, Small P. Polymyositis/Dermatomyositis: clinical features and outcome in 22 patients. J Derm 1985;12:283-6.
55. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H. Plymyositis and dermatomyositis: short-term and long-term outcome, and predictive factors of prognosis. J Derm 2001;28:2230-7.
56. Mustafa KN, Dahbour SS. Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol 2010;29:1381-5.
57. Tani K, Tomioka R, Sato K, Furukawa C, Nakajima T, Toyota Y, Shimizu T et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. Journal of Medicine Investigation 2007;54:295-302.
58. Scaling ST, Kaufman RH, Pattern BM. Dermatomyositis and female malignancy. Obstet Gynecol 1979;54:474-7.
59. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine 1994;73:153-7.
60. Maugars YM, Berthlot JMM, Abbas AA, Mussini JMB, Nguyen JMD, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996;14:263-74.
61. Cherin P, Piette JC, Herson S, Bletry O, Wechsler B, Frances C, Godeau P. Dermatomyositis and ovarian cancer: a report of 7 cases and literature review. J Rheumatol 1993;20:1897-8.
62. Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. European Review for Medical and PPharmacological Sciences 2009;13:77-80.
63. Amerio P, Girardinelli CR, Proietto G, Forleo P, Cerritelli L, Feliciani C, Colonna L et al. Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 2002;12:165-9.
64. Peng JC, Sheen TS, Hsu MM. Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 1995;121:1298-301.
65. Mebazaa A, Boussen H, Nouira R, Rokbani L, Osman-Dhahri AB, Bouaouina N et al. Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol 2003;48:530-4.
66. Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. Dermatologica 1990;180:212-6.
67. Andràs C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Dankò K. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008;35:438-44.
68. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WFC. Malignancy is associated with dermatmyositis but not polymyositis in Northern New England, USA. J Rheumatol 2009;36:2704-10.
69. Manchul LA, Jin A, Pritchard KI, Tenenbaum J, Boyd NF, Lee P et al. The frequency of malignant neoplasms in patients with polymy-ositis-dermatomyositis. Arch Inter Med 1985;145:1835-39.
70. Mahè E, Descamps V, Burnouf M, Crickx B. A help clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis. Arch Dermatol 2003; 139:539.
71. Dawkins M, Jorizzo J, Walter FO, Albertson D, Sinai SH, Hind A. Dermatomyositis: A dermatology-based case series. J Am Acad Dermatol 1998;38:397-404.
72. Amoura Z, Duhaut P, Huong DLT, Wechsler B, Costedoat-Chalumeau N, Frances C et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005;14:1279-82.
73. Goh CL, Raj VS. Dermatomyositis in a skin clinic. Annals Academy of Medicine 1983;12:1-12.
74. Ang P, Sugeng MW, Chua SH. Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 2000;29:219-23.
75. Lynn SJ, Sawyers SM, Moller PW, O'Donnel JL, Chapman PT. Adult-onset inflammatory myopathy: North Canterbury experience 1989-2001. Internal Medicine Journal 2005;35:170-3.
76. Fardet L, Rybojad M, Gain M, Kettaneh A, Cherin P, Bachelez H, Dubertret L et al. Incidence, risk factors, and severity of Herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009;145:889-93.
77. Teh CL, Wong JS, Soo HH. Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak general hospital. Rheumatol Int 2012;32:265-8.
78. Santo AA, Souza JMP, Pinheiro CE, Souza DCC, Sato EI. Trends in dermatomyositis - and polymyositis-related mortality in the state of Sao Paulo, Brazil, 1985-2007: multiple cause-of-death analysis. BMC Public Health 210;10:597.
79. Selvaag E, Austad J. Dermatomyositis and malignancy. Clinical and Experimental Dermatology 1996;21:463-4.
80. Chen YJ, WU CY, Shen JL. Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 2007;87:33-8.
81. Kubo M, Ihn H, Asano Y, Yamane K, Jazawa N, Tamaki K. Prevalence of 52 Kd and 60-Kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis. J Am Acad Dermatol 2002;47:148-51.
82. Scola RH, Werneck LC, Prevedello DMS, Toderke EL, Iwamoto FFM. Diagnosis of dermatomyositis and polymyositis. A study of 102 cases. Arq Neuropsiquiatr 2000;58(3b):789-99.
83. Selva-O'Callaghan A, Trallero-Aragùas E, Grau-Junyent JM, Labrador-Horillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010;22:727-32.
84. Trallero-Araguàs E, Labrador-Horillo M, Selva-O'Callaghan A, Martinez-Gomez X, Palou E, Rodriguez-Sanchez JL, Vilardell-Tarrès M. Cancer associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010;89:47-52.
85. Chinoy H, Ferting N, Oddis CV, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.
86. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita HO et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007;46:25-8.
87. Hengstman GJD, Egberts WTMV, Seelig HP, Lundberg IE, Mout-sopoulos HM, Doria A, Mosca M et al. Clinical characteristics of patients with myositis and autoatibodies to different fragments of the Mi-2ß antigen. Ann Rheum Dis 2006;65:242-5.
88. Hoshino K, Muro Y, Sugiura K, Tornita Y, Nakashima R, Minori T. Anti-MDA5 and anti-TIF-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010;49:1726-33.
89. Marie I, Lahaxe L, Benveniste O, Delavigne KK, Adoue D, Mouthon L et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010;162:337-44.
90. Targoff IN, Manyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
91. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H et al. Clinical association of autoantibodies to ap155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008;47:324-8.
92. Callen JP. Myositis and malignancy. Curr Opin Rheumatol 1994;6:590-4.
93. Jorizzo JL. Dermatomyositis: praticai aspects. Arch Dermatol 2002;138:114-6.
94. Zampieri S, Valente M, Adami N, Biral D, Ghirardello A, Rampudda ME, Vecchiato M et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010;9: 449-53.
95. Casciola Ronsen L, Nagaraju K, Poltz P, Wang K, Levine S, Gabri-elson E, Corse A et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. JEM 2005;201:591-601.
96. Love LA, Leff RL, Fraser DD, Targoff I, Dalakas M, Plötz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.